Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + trastuzumab + XELOX first-line study in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300074767Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib, trastuzumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoints: Progression-free survival and Safety. Started Aug 2023; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300074767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074767.